肌萎缩侧索硬化症啮齿动物模型。

Q2 Pharmacology, Toxicology and Pharmaceutics
Thomas Philips, Jeffrey D Rothstein
{"title":"肌萎缩侧索硬化症啮齿动物模型。","authors":"Thomas Philips, Jeffrey D Rothstein","doi":"10.1002/0471141755.ph0567s69","DOIUrl":null,"url":null,"abstract":"Amyotrophic Lateral Sclerosis (ALS) is a motor neuron disease affecting upper and lower motor neurons in the central nervous system. Patients with ALS develop extensive muscle wasting and atrophy leading to paralysis and death 3 to 5 years after disease onset. The condition may be familial (fALS 10%) or sporadic ALS (sALS, 90%). The large majority of fALS cases are due to genetic mutations in the Superoxide dismutase 1 gene (SOD1, 15% of fALS) and repeat nucleotide expansions in the gene encoding C9ORF72 (∼40% to 50% of fALS and ∼10% of sALS). Studies suggest that ALS is mediated through aberrant protein homeostasis (i.e., ER stress and autophagy) and/or changes in RNA processing (as in all non‐SOD1‐mediated ALS). In all of these cases, animal models suggest that the disorder is mediated non‐cell autonomously, i.e., not only motor neurons are involved, but glial cells including microglia, astrocytes, and oligodendrocytes, and other neuronal subpopulations are also implicated in the pathogenesis. Provided in this unit is a review of ALS rodent models, including discussion of their relative advantages and disadvantages. Emphasis is placed on correlating the model phenotype with the human condition and the utility of the model for defining the disease process. Information is also presented on RNA processing studies in ALS research, with particular emphasis on the newest ALS rodent models. © 2015 by John Wiley & Sons, Inc.","PeriodicalId":10871,"journal":{"name":"Current Protocols in Pharmacology","volume":"69 ","pages":"5.67.1-5.67.21"},"PeriodicalIF":0.0000,"publicationDate":"2015-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/0471141755.ph0567s69","citationCount":"161","resultStr":"{\"title\":\"Rodent Models of Amyotrophic Lateral Sclerosis.\",\"authors\":\"Thomas Philips, Jeffrey D Rothstein\",\"doi\":\"10.1002/0471141755.ph0567s69\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Amyotrophic Lateral Sclerosis (ALS) is a motor neuron disease affecting upper and lower motor neurons in the central nervous system. Patients with ALS develop extensive muscle wasting and atrophy leading to paralysis and death 3 to 5 years after disease onset. The condition may be familial (fALS 10%) or sporadic ALS (sALS, 90%). The large majority of fALS cases are due to genetic mutations in the Superoxide dismutase 1 gene (SOD1, 15% of fALS) and repeat nucleotide expansions in the gene encoding C9ORF72 (∼40% to 50% of fALS and ∼10% of sALS). Studies suggest that ALS is mediated through aberrant protein homeostasis (i.e., ER stress and autophagy) and/or changes in RNA processing (as in all non‐SOD1‐mediated ALS). In all of these cases, animal models suggest that the disorder is mediated non‐cell autonomously, i.e., not only motor neurons are involved, but glial cells including microglia, astrocytes, and oligodendrocytes, and other neuronal subpopulations are also implicated in the pathogenesis. Provided in this unit is a review of ALS rodent models, including discussion of their relative advantages and disadvantages. Emphasis is placed on correlating the model phenotype with the human condition and the utility of the model for defining the disease process. Information is also presented on RNA processing studies in ALS research, with particular emphasis on the newest ALS rodent models. © 2015 by John Wiley & Sons, Inc.\",\"PeriodicalId\":10871,\"journal\":{\"name\":\"Current Protocols in Pharmacology\",\"volume\":\"69 \",\"pages\":\"5.67.1-5.67.21\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2015-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1002/0471141755.ph0567s69\",\"citationCount\":\"161\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Protocols in Pharmacology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/0471141755.ph0567s69\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Protocols in Pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/0471141755.ph0567s69","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 161

摘要

肌萎缩侧索硬化症(ALS)是一种影响中枢神经系统上、下运动神经元的运动神经元疾病。肌萎缩侧索硬化症患者在发病后3至5年出现广泛的肌肉萎缩和萎缩,导致瘫痪和死亡。这种疾病可能是家族性的(fALS占10%)或散发性的(sALS占90%)。绝大多数fALS病例是由于超氧化物歧化酶1基因(SOD1, fALS的15%)的基因突变和编码C9ORF72基因的重复核苷酸扩增(fALS的40%至50%和sALS的10%)。研究表明,ALS是通过异常蛋白稳态(即内质网应激和自噬)和/或RNA加工的改变(如所有非sod1介导的ALS)介导的。在所有这些病例中,动物模型表明该疾病是非细胞自主介导的,即不仅涉及运动神经元,而且包括小胶质细胞、星形胶质细胞和少突胶质细胞在内的胶质细胞和其他神经元亚群也与发病机制有关。本单元提供了ALS啮齿动物模型的综述,包括讨论它们的相对优点和缺点。重点放在模型表型与人类状况的相关性和模型用于定义疾病过程的效用上。还介绍了ALS研究中的RNA加工研究,特别强调了最新的ALS啮齿动物模型。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Rodent Models of Amyotrophic Lateral Sclerosis.
Amyotrophic Lateral Sclerosis (ALS) is a motor neuron disease affecting upper and lower motor neurons in the central nervous system. Patients with ALS develop extensive muscle wasting and atrophy leading to paralysis and death 3 to 5 years after disease onset. The condition may be familial (fALS 10%) or sporadic ALS (sALS, 90%). The large majority of fALS cases are due to genetic mutations in the Superoxide dismutase 1 gene (SOD1, 15% of fALS) and repeat nucleotide expansions in the gene encoding C9ORF72 (∼40% to 50% of fALS and ∼10% of sALS). Studies suggest that ALS is mediated through aberrant protein homeostasis (i.e., ER stress and autophagy) and/or changes in RNA processing (as in all non‐SOD1‐mediated ALS). In all of these cases, animal models suggest that the disorder is mediated non‐cell autonomously, i.e., not only motor neurons are involved, but glial cells including microglia, astrocytes, and oligodendrocytes, and other neuronal subpopulations are also implicated in the pathogenesis. Provided in this unit is a review of ALS rodent models, including discussion of their relative advantages and disadvantages. Emphasis is placed on correlating the model phenotype with the human condition and the utility of the model for defining the disease process. Information is also presented on RNA processing studies in ALS research, with particular emphasis on the newest ALS rodent models. © 2015 by John Wiley & Sons, Inc.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Current Protocols in Pharmacology
Current Protocols in Pharmacology Pharmacology, Toxicology and Pharmaceutics-Pharmacology
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信